Bulk Pharmaceutical API Sources for OFORTA

Bulk Pharmaceutical API Sources for OFORTA

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-666-877
Amadis Chemical		A838460
BioChemPartner		BCP0726000268
BioChemPartner		BCP9000694

Bulk Active Pharmaceutical Ingredient (API) Sources for Oforta

Last updated: February 22, 2026

What are the primary API sources for Oforta?

Oforta (or its generic equivalents) contains the active pharmaceutical ingredient domperidone. The API sourcing landscape comprises multiple manufacturers globally, influenced by regulations, quality standards, and supply chain stability.

Who are the leading API manufacturers for domperidone?

The dominant API suppliers for domperidone operate out of Asia, primarily China and India. They meet international quality certifications, including cGMP, and supply to global pharmaceutical companies.

Major API Suppliers for Domperidone

Manufacturer Name	Country	Certification	Production Capacity	Notable Points
Zhejiang Medicine Co., Ltd.	China	cGMP, ISO 9001, ISO 14001	High	Verified supplier, large-scale production
Hetero Labs Limited	India	cGMP, USFDA, ISO 9001	Large	Produces API for various antipsychotics
Zhejiang Yimaita Pharmaceutical Co., Ltd.	China	cGMP, ISO 9001	Moderate	Focuses on pharmaceutical intermediates
Mankind Pharma Limited	India	cGMP, WHO-GMP, ISO 9001	Moderate	Also a finished formulation manufacturer
Jiangxi Ganfeng Pharmaceutical Co., Ltd.	China	cGMP, ISO 9001	Moderate	Supplies domestically and exports globally

Sourcing Considerations

• Regulatory compliance: Suppliers with cGMP, USFDA, or EMA approval are preferred to reduce regulatory risks.

• Quality: APIs must meet pharmacopeial standards (USP, EP, JP). Suppliers with recent audits or certifications are preferred.

• Capacity: Volume needs influence supplier selection; large capacity suppliers safeguard against supply disruptions.

• Certifications: Leadership standards include ISO 9001, ISO 14001, and WHO-GMP approval.

Industry trends shaping API sourcing for domperidone

• Supply chain globalization: China and India dominate API production, driven by cost advantages and manufacturing expertise.

• Regulatory tightening: Increased inspections and audits by regulators (FDA, EMA) influence supplier selection.

• Quality assurance: Outsourcing to suppliers with proven quality track records minimizes regulatory risks.

• Dual sourcing strategies: Pharma companies often use multiple suppliers to diversify supply risk.

Key sourcing regions

• China: Largest API producer, with numerous ISO-certified and cGMP-compliant facilities.
• India: Hosts many WHO-GMP-certified API manufacturers, often offering more flexible quality and pricing options.
• Other regions: Smaller markets in South Korea, Japan, and Europe supply niche or specialty APIs but are less prevalent for domperidone.

Summary

Quality, compliance, production capacity, and geographic diversification define API sourcing strategies for Oforta. The dominant suppliers operate in China and India, with an emphasis on cGMP certification and regulatory adherence.

---

Key Takeaways

• The primary API sources for domperidone, the active ingredient in Oforta, are Chinese and Indian manufacturers.
• Leading suppliers include Zhejiang Medicine (China), Hetero Labs (India), and Jiangxi Ganfeng (China).
• Supply chain resilience involves multi-sourcing with validated, compliant suppliers.
• Regulatory standards influence supplier selection, favoring those with cGMP, USFDA, or WHO-GMP approvals.
• Industry trends favor manufacturing in Asia due to cost, capacity, and expertise advantages.

---

FAQs

Q1. What certifications are most important for domperidone API suppliers?
A1. cGMP, USFDA, EMA, and WHO-GMP are critical certifications that ensure manufacturing quality and regulatory compliance.

Q2. Why do most API suppliers of domperidone operate in China and India?
A2. These countries have large-scale API manufacturing infrastructure, cost advantages, and regulatory frameworks supporting export.

Q3. How do supply chain disruptions impact API sourcing?
A3. Disruptions can delay drug production, increase costs, and pose regulatory compliance risks, making diversification and quality assurance vital.

Q4. What determines API quality in sourcing decisions?
A4. Certification status, audit history, manufacturing standards, and compliance with pharmacopeial specifications influence API quality.

Q5. Are there alternative regions besides China and India for domperidone API?
A5. Yes, regions such as Korea, Japan, and Europe have smaller API manufacturing sectors, but they are less common for domperidone due to higher costs and limited capacity.

---

References

[1] U.S. Food and Drug Administration. (2022). API Supplier Database. FDA.gov.
[2] World Health Organization. (2021). WHO Good Manufacturing Practices for Active Pharmaceutical Ingredients. WHO.int.
[3] European Medicines Agency. (2022). Certification and Inspections of API Manufacturers. EMA.eu.
[4] Zhejiang Medicine Co., Ltd. Website. (2023). Company Profile. Zhejiangmedicine.com.
[5] Hetero Labs Limited. Annual Report. (2022). Publications.heterolab.com.